MaaT Pharma Reports Financial Results for the Third Quarter 2026
Business Wire•16/11/2026•12:00 ET
0
Key Highlights
- ➤Cash EUR 10.1 million at September 30, down from EUR 24.9 million year-end 2025
- ➤Cash runway estimated through December 2026, including EUR 3.7 million tax credit
- ➤Q3 revenue EUR 0.5 million; nine-month revenue EUR 1.6 million
- ➤Company actively exploring financing opportunities and strategic partnerships
- ➤Pre-transition nine-month revenue would have been EUR 3.3 million, versus EUR 3.4 million in 2025
MaaT Pharma Reports Financial Results for the Third Quarter 2026
* Revenues of EUR 0.5 million in the third quarter of 2026 and EUR 1.6 million year-to-date, derived from the Early Access Program
Get started
Create a free account to read the full story.
